¥1,592.00
0.38% today
Tokyo, Oct 16, 02:45 am CET
ISIN
JP3942400007
Symbol
4503
Index

Astellas Pharma Target price 2025 - Analyst rating & recommendation

Astellas Pharma Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
5%

Astellas Pharma Price Target

Target Price ¥1,683.00
Price ¥1,586.00
Potential
Number of Estimates 16
16 Analysts have issued a price target Astellas Pharma 2026 . The average Astellas Pharma target price is ¥1,683.00. This is higher than the current stock price. The highest price target is
¥2,310.00 45.65%
register free of charge
, the lowest is
¥1,313.00 17.21%
register free of charge
.
A rating was issued by 19 analysts: 9 Analysts recommend Astellas Pharma to buy, 9 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2026 of . Most analysts recommend the Astellas Pharma stock at Buy or hold.

Sales and Margin forecast 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Billion ¥ 1,912.32 2,012.13
19.25% 5.22%
EBITDA Margin 20.93% 22.51%
50.25% 7.53%
Net Margin 2.65% 8.40%
149.67% 216.54%

16 Analysts have issued a sales forecast Astellas Pharma 2026 . The average Astellas Pharma sales estimate is

¥2.0t
Unlock
. This is
3.45% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
¥2.2t 13.29%
Unlock
, the lowest is
¥1.8t 5.22%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 ¥1.9t 19.25%
2026
¥2.0t 5.22%
Unlock
2027
¥2.1t 4.56%
Unlock
2028
¥1.9t 9.05%
Unlock

13 Analysts have issued an Astellas Pharma EBITDA forecast 2026. The average Astellas Pharma EBITDA estimate is

¥453b
Unlock
. This is
106.34% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
¥613b 179.45%
Unlock
, the lowest is
¥318b 45.06%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 ¥400b 79.17%
2026
¥453b 13.15%
Unlock
2027
¥532b 17.39%
Unlock
2028
¥493b 7.24%
Unlock

EBITDA Margin

2025 20.93% 50.25%
2026
22.51% 7.53%
Unlock
2027
25.27% 12.26%
Unlock
2028
25.77% 1.98%
Unlock

15 Astellas Pharma Analysts have issued a net profit forecast 2026. The average Astellas Pharma net profit estimate is

¥169b
Unlock
. This is
107.10% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
¥335b 310.42%
Unlock
, the lowest is
¥110b 35.47%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 ¥50.7b 197.72%
2026
¥169b 232.88%
Unlock
2027
¥236b 39.44%
Unlock
2028
¥215b 8.67%
Unlock

Net Margin

2025 2.65% 149.67%
2026
8.40% 216.54%
Unlock
2027
11.20% 33.33%
Unlock
2028
11.24% 0.36%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share ¥ 28.24 94.31
198.20% 233.96%
P/E 16.82
EV/Sales 1.77

15 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma EPS is

¥94.31
Unlock
. This is
107.59% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
¥186.90 311.40%
Unlock
, the lowest is
¥61.69 35.79%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 ¥28.24 198.20%
2026
¥94.31 233.96%
Unlock
2027
¥131.51 39.44%
Unlock
2028
¥120.11 8.67%
Unlock

P/E ratio

Current 34.91 39.27%
2026
16.82 51.82%
Unlock
2027
12.06 28.30%
Unlock
2028
13.20 9.45%
Unlock

Based on analysts' sales estimates for 2026, the Astellas Pharma stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.83 14.08%
2026
1.77 3.45%
Unlock
2027
1.69 4.36%
Unlock
2028
1.86 9.95%
Unlock

P/S ratio

Current 1.50 16.04%
2026
1.45 3.34%
Unlock
2027
1.39 4.36%
Unlock
2028
1.53 9.95%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today